Re: Response letter to Sanofi's communication related to "the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States".
Saved in:
| Title: | Re: Response letter to Sanofi's communication related to "the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States". |
|---|---|
| Authors: | Farahbakhshian S; US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA., Inocencio TJ; Modeling and Meta-analysis, OPEN Health, Bethesda, MD, USA., Poorman G; Modeling and Meta-analysis, OPEN Health, Bethesda, MD, USA., Wright E; US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA., Pathak RR; US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA., Bullano M; US Medical, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA. |
| Source: | Journal of medical economics [J Med Econ] 2023 Jan-Dec; Vol. 26 (1), pp. 581-583. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Comment |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
